IP
Innate Pharma S.A.
IPH.PA · PAR
1.54 € -1.66% (-0.03 €)
1M -12.15%
Market Cap 146.9M €
P/E Ratio -
Div. Yield -
ROE 933.59%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 52.70x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 61.71%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
Net margin 1,764.51%
Op. margin 2,058.02%
Quality
1 /100
Poor ROIC 146.05%
ROE 933.59%
ROA 78.41%
Debt
24 /100
High Current ratio 1.27x
Int. coverage -18.38x
Debt/Equity N/A
Stability
26 /100
Unstable Beta 0.88x
Rev. volatility 46.98%
EPS volatility 346.68%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o IPH.PA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jonathan E. Dickinson
Employees
164
Headquarters
Marseille
Nadchodzące wydarzenia
17 WRZ
Earnings
Upcoming earnings report